Andrea Necchi

Also affiliated with Mylan (South Africa)

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 8 papers. Top paper: “Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up”.

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

Annals of Oncology(2022)10.1016/j.annonc.2022.11.012

N/A

3.4DataRank · unranked

116 citations

Daniel Castellano, Petros Grivas, David J. Vaughn, Thomas Powles, Jacqueline Vuky +15 more

Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial

The Lancet Oncology(2024)10.1016/s1470-2045(24)00178-5

N/A

0.678DataRank · unranked

91 citations

Mathieu Roumiguié, Ashish M Kamat, Neal D Shore, Joost L Boormans, Ahmet Adil Esen +17 more

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3089

N/A

0.587DataRank · unranked

49 citations

Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae‐Lyun Lee +26 more

MP55-19 IMPACT OF HISTOLOGICAL VARIANTS IN NODE POSITIVE PATIENTS TREATED WITH RADICAL CYSTECTOMY FOR BLADDER CANCER

The Journal of Urology(2020)10.1097/ju.0000000000000924.019

N/A

0DataRank · unranked

0 citations

Emanuele Zaffuto, Simone Scuderi, Andrea Salonia, Roberta Lucianò, Filippo Pederzoli +12 more

End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer

Journal of Clinical Oncology(2025)10.1200/jco-25-01608

N/A

0DataRank · unranked

16 citations

Matthew D. Galsky, Nazlı Dizman, David H. Aggen, Neeraj Agarwal, Hikmat Al‐Ahmadie +39 more

1950P Squamous cell carcinoma of unknown primary (SCCUP): A genomic landscape study

Annals of Oncology(2024)10.1016/j.annonc.2024.08.2035

N/A

0DataRank · unranked

0 citations

Stephanie Lakritz, D.C. Pavlick, S. Lindsey Davis, Christopher H. Lieu, Corinna Eule +15 more

Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy

The Journal of Urology(2021)10.1097/ju.0000000000002261

N/A

0DataRank · unranked

59 citations

Joep J. de Jong, Vinnie Y. T. Liu, Tarek A. Bismar, Stephen A. Boorjian, Huei-Chung Huang +10 more

Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad155

N/A

0DataRank · unranked

56 citations

Amin H. Nassar, Gregory R. Pond, Tony Zhuang, Viraj A. Master, Bassel Nazha +50 more